Emend and Cosmegen drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Emend (aprepitant) and Cosmegen (dactinomycin). Common drug interactions include platelet count decreased among females and convulsion among males.

The phase IV clinical study analyzes what interactions people have when they take Emend and Cosmegen. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Emend?

Emend has active ingredients of aprepitant. It is often used in nausea. eHealthMe is studying from 13,741 Emend users. Check the latest studies of Emend.

What is Cosmegen?

Cosmegen has active ingredients of dactinomycin. eHealthMe is studying from 937 Cosmegen users. Check the latest studies of Cosmegen.



On Jul, 16, 2026

12 people who take Emend and Cosmegen together, and have interactions are studied.

Emend and Cosmegen drug interactions.

What are the common drug interactions of Emend and Cosmegen, by gender? *:

female:

  1. Platelet count decreased
  2. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  3. Anaemia (lack of blood)
  4. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  5. Pyrexia (fever)
  6. White blood cell count decreased
  7. Encephalopathy (functioning of the brain is affected by some agent or condition)
  8. Agitation (state of anxiety or nervous excitement)
  9. Altered state of consciousness (altered state of mind)
  10. Facial pain

male:

  1. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  2. Febrile bone marrow aplasia (bone marrow greatly decreases or stops production of blood cells)
  3. Pyelonephritis acute (sudden inflammation of kidney caused by bacteria)
  4. Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage))
  5. Therapeutic response decreased (less preventive response)
  6. Tonic convulsion (the person will quickly lose consciousness and the skeletal muscles will suddenly tense, often causing the extremities to be pulled towards the body or rigidly pushed away from it)
  7. Areflexia (absence of a reflex)
  8. Cerebellar syndrome (impaired blood circulation to cerebellum due to lesion in artery)
  9. Device related infection
  10. Diarrhoea

What are the common drug interactions of Emend and Cosmegen, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. White blood cell count decreased
  2. Encephalopathy (functioning of the brain is affected by some agent or condition)
  3. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  4. Febrile bone marrow aplasia (bone marrow greatly decreases or stops production of blood cells)
  5. Agitation (state of anxiety or nervous excitement)
  6. Altered state of consciousness (altered state of mind)
  7. Areflexia (absence of a reflex)
  8. Cerebellar syndrome (impaired blood circulation to cerebellum due to lesion in artery)
  9. Device related infection
  10. Diarrhoea

20-29:

n/a

30-39:

  1. Facial pain
  2. Hepatic enzyme increased
  3. Rash generalised (rash on most of body parts)
  4. Swelling face
  5. White blood cell disorder

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

  1. Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 6 people, 50.00%
  2. Wilms Tumor (cancer of the kidneys that typically occurs in children): 1 person, 8.33%
  3. Sarcoma (rare cancers that develop in the muscle, bone, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues): 1 person, 8.33%
  4. Gestational Trophoblastic Disease (disease of foetus surrounding during pregnancy): 1 person, 8.33%
  5. Bone Marrow Failure: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Emend and Cosmegen?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Emend and Cosmegen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Emend:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Cosmegen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Emend and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cosmegen and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on aprepitant and dactinomycin (the active ingredients of Emend and Cosmegen, respectively), and Emend and Cosmegen (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: